Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 20;20(12):3011.
doi: 10.3390/ijms20123011.

Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury

Affiliations
Review

Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury

Sara J Holditch et al. Int J Mol Sci. .

Abstract

Cisplatin is a widely used chemotherapeutic agent used to treat solid tumours, such as ovarian, head and neck, and testicular germ cell. A known complication of cisplatin administration is acute kidney injury (AKI). The development of effective tumour interventions with reduced nephrotoxicity relies heavily on understanding the molecular pathophysiology of cisplatin-induced AKI. Rodent models have provided mechanistic insight into the pathophysiology of cisplatin-induced AKI. In the subsequent review, we provide a detailed discussion of recent advances in the cisplatin-induced AKI phenotype, principal mechanistic findings of injury and therapy, and pre-clinical use of AKI rodent models. Cisplatin-induced AKI murine models faithfully develop gross manifestations of clinical AKI such as decreased kidney function, increased expression of tubular injury biomarkers, and tubular injury evident by histology. Pathways involved in AKI include apoptosis, necrosis, inflammation, and increased oxidative stress, ultimately providing a translational platform for testing the therapeutic efficacy of potential interventions. This review provides a discussion of the foundation laid by cisplatin-induced AKI rodent models for our current understanding of AKI molecular pathophysiology.

Keywords: AKI; acute kidney injury; apoptosis; cisplatin; inflammation; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The complex pathophysiology of cisplatin-induced AKI. (I.) autophagosome/lysosome. (II.) mitochondria (III.) fragmented DNA (cell death). Abbreviations: organic cation transporters (OCTs), multidrug resistance-associated proteins (MRPs), multi-antimicrobial extrusion protein (MATEs), chemokine (C-X-C motif) ligand (CXCL), chemokine (C-C motif) ligand (CCL), interleukin-1 beta (IL-1β), tumour necrosis factor (TNF). blood urea nitrogen (BUN), serum creatinine (SCr) kidney injury molecule-1 (KIM-1), neutrophil gelatinase –associated lipocalin (NGAL), interleukin-18 (IL-18).

References

    1. Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364–378. doi: 10.1016/j.ejphar.2014.07.025. - DOI - PMC - PubMed
    1. Oh G.S., Kim H.J., Shen A., Lee S.B., Khadka D., Pandit A., So H.S. Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. Electrolyte Blood Press. 2014;12:55–65. doi: 10.5049/EBP.2014.12.2.55. - DOI - PMC - PubMed
    1. Rahman M., Shad F., Smith M.C. Acute kidney injury: A guide to diagnosis and management. Am. Fam. Physician. 2012;86:631–639. - PubMed
    1. George B., Joy M.S., Aleksunes L.M. Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp. Biol. Med. (Maywood) 2018;243:272–282. doi: 10.1177/1535370217745302. - DOI - PMC - PubMed
    1. Harrill A.H., Lin H., Tobacyk J., Seely J.C. Mouse population-based evaluation of urinary protein and miRNA biomarker performance associated with cisplatin renal injury. Exp. Biol. Med. (Maywood) 2018;243:237–247. doi: 10.1177/1535370217740854. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources